By 2019, the Commission shall review the regulatory framework for fees payable to the Agency in relation to medicinal products for human use and veterinary medicinal products. The Commission shall put forward, as appropriate, legislative proposals with a view to update that framework. When reviewing the regulatory framework for fees payable to the Agency, the Commission shall pay attention to potential risks related to the fluctuations in the fee revenue of the Agency.
Art. 86a Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…
In forcesince 28 Jan 2019cited 1×
Regulation (EU) 2019/5Lawamends